We applied these methods to study the effects of MRTX1257, a mutant-specific inhibitor of the KRAS G12C oncoprotein, on the TME of an immunotherapy refractory KRAS G12C mutant lung cancer. This evidence concerns the gene KRAS and lung carcinoma.